PET/MR:Techniques, Indications and Applications

Similar documents
PET-MRI in malignant bone tumours. Lars Stegger Department of Nuclear Medicine University Hospital Münster, Germany

Bone PET/MRI : Diagnostic yield in bone metastases and malignant primitive bone tumors

Dr Sneha Shah Tata Memorial Hospital, Mumbai.

Optimized. clinical pathway. propels high utilization of PET/MR at Pitié-Salpêtrière Hospital

MRI-PET: Oncologic Applications

Introduction Pediatric malignancies Changing trends & Radiation burden Radiation exposure from PET/CT Image gently PET & CT modification - PET/CT

Los Angeles Radiological Society 62 nd Annual Midwinter Radiology Conference January 31, 2010

Case Reports: Tumor Detection by Diffusion-Weighted MRI and ADC-Mapping with Correlation to PET/CT Results

Hybrid systems in Medical Imaging

8/10/2016. PET/CT for Tumor Response. Staging and restaging Early treatment response evaluation Guiding biopsy

Nuclear medicine in oncology. 1. Diagnosis 2. Therapy

PET IMAGING (POSITRON EMISSION TOMOGRAPY) FACT SHEET

POSITRON EMISSION TOMOGRAPHY (PET)

The Proper Use of PET/CT in Tumoring Imaging

PSMA PET SCANNING AND THERANOSTICS IN PROSTATE CANCER KEVIN TRACEY, MD, FRCPC PRECISION DIAGNSOTIC IMAGING REGIONAL PET/CT CENTRE

Page: 1 of 29. For this policy, PET scanning is discussed for the following 4 applications in oncology:

Radionuclide detection of sentinel lymph node

Oncologic Applications of PET Scanning

Nuclear Medicine in Oncology

PET CT for Staging Lung Cancer

PET Scan in Practice for CHI

Emerging Referral Patterns for Whole-Body Diffusion Weighted Imaging (WB-DWI) in an Oncology Center

2004 SNM Mid-Winter Educational Symposium

ROLE OF PET-CT SCAN IN LOCALLY ADVANCED HEAD & NECK CANCER: A Prospective Study

Principles of nuclear metabolic imaging. Prof. Dr. Alex Maes AZ Groeninge Kortrijk and KULeuven Belgium

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

PET/CT Frequently Asked Questions

SELF-ASSESSMENT MODULE REFERENCE SPR 2018 Oncologic Imaging Course Adrenal Tumors November 10, :00 12:10 p.m.

FieldStrength. Leuven research is finetuning. whole body staging

Molecular Imaging and Cancer

PET/CT and PET/MR of Cardiac Tumors

Colorectal Cancer and FDG PET/CT

Nuclear Medicine and PET. D. J. McMahon rev cewood

Nuclear Medicine in the Diabetic Foot

Whole Body MRI. Dr. Nina Tunariu. Prostate Cancer recurrence, progression and restaging

PET/CT in lung cancer

Index. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type.

Nuclear Medicine: Basics to therapy

PET-CT for radiotherapy planning in lung cancer: current recommendations and future directions

Chapter 10. Summary, conclusions and future perspectives

Quantitative Nuclear Medicine Imaging in Oncology. Susan E. Sharp, MD

Nuclear Sciences and Medicine

What Radiologists do?

Indications of PET/CT in oncology

PET/CT in oncology. Positron emission tomography

4D PET: promises and limitations

Nuclear Medicine in Thyroid Cancer. Phillip J. Koo, MD Division Chief of Diagnostic Imaging

PET/MRI: a new era in multimodality molecular imaging

FDG PET/CT STAGING OF LUNG CANCER. Dr Shakher Ramdave

Nuclear Medicine Head and Neck Region. Bán Zsuzsanna, MD University of Pécs, Department of Nuclear Medicine

MR Tumor Staging for Treatment Decision in Case of Wilms Tumor

Assessment of renal cell carcinoma by two PET tracer : dual-time-point C-11 methionine and F-18 fluorodeoxyglucose

Short summary of published results of PET with fluoromethylcholine (18F) in prostate cancer

Optimized PET/CT protocols: how much CT is needed? Increasing use of PET-CT. Imaging in Lymphoma

Theranostics in Nuclear Medicine

Prof. Dr. NAGUI M. ABDELWAHAB,M.D.; MARYSE Y. AWADALLAH, M.D. AYA M. BASSAM, Ms.C.

A Snapshot on Nuclear Cardiac Imaging

CT Optimisation for Paediatric SPECT/CT Examinations. Sarah Bell

Hybrid Imaging SPECT/CT PET/CT PET/MRI. SNMMI Southwest Chapter Aaron C. Jessop, MD

PROGRAMME OVERVIEW Saturday, October 13, 2018

Integrated PET/CT systems State of the art and Clinical Applications

Understanding the Diagnostic and Prognostic Role of Imaging in the Evaluation of an Anterior Mediastinal Mass

General Nuclear Medicine

Molecular Imaging Guided Therapy: The Perfect Storm. David M Schuster, MD Emory University Department of Radiology Atlanta, GA

New imaging techniques: let there be light. Felix M. Mottaghy Department of Nuclear Medicine University Hospital KU Leuven

F NaF PET/CT in the Evaluation of Skeletal Malignancy

Imaging Pancreatic Neuroendocrine Tumors (PNETs): CT, MRI, EUS, Nuclear

PET Imaging in Langerhans Cell Histiocytosis

PET/CT in Breast Cancer

Positron Emission Tomography (PET) for Staging Low-Grade Non-Hodgkin s Lymphomas (NHL)

THE ROLE OF CONTEMPORARY IMAGING AND HYBRID METHODS IN THE DIAGNOSIS OF CUTANEOUS MALIGNANT MELANOMA(CMM) AND MERKEL CELL CARCINOMA (MCC)

FDG-PET/CT for cancer management

The Use of PET Scanning in Urologic Oncology

Table 1. Some other positron tracers with applications in oncology.

Understanding Biological Activity to Inform Drug Development

PET/MR. Are You Ready?? Derek Lee, BS, CNMT, PET

Applications of PET in medicine and biomedical studies

Introduction. Methods and materials. 68 Ga-DOTATATE PET CT imaging in carotid body paragangliomas. Patients

The Role of PET / CT in Lung Cancer Staging

Using PET/CT in Prostate Cancer

Typical PET Image. Elevated uptake of FDG (related to metabolism) Lung cancer example: But where exactly is it located?

First Clinical Experience with

Clinical indications for positron emission tomography

Positron emission tomography/computer tomography in the evaluation of head and neck cancer treatment

Testicular relapse of non-hodgkin Lymphoma noted on FDG-PET

New Visions in PET: Surgical Decision Making and PET/CT

Lymphoma Read with the experts

MRI in lymphoma: where are we in 2016

4th INTERNATIONAL WORKSHOP ON INTERIM-PET IN LYMPHOMA Palais de l Europe, Menton Oct 4-5, 2012

performed to help sway the clinician in what the appropriate diagnosis is, which can substantially alter the treatment of management.

UK Musculoskeletal Oncology: Something for All Ages. Lars Wagner, MD Pediatric Hematology/Oncology University of Kentucky

PET-MRI in Cardiac Imaging: Initial Experience

MEASUREMENT OF EFFECT SOLID TUMOR EXAMPLES

Positron Emission Tomography in Lung Cancer

The Importance of PET/CT in Human Health. Homer A. Macapinlac, M.D.

Jeffrey C. Weinreb, MD, FACR Yale School of Medicine Yale-New Haven Hospital

FDG PET/CT Versus I-131 MIBG Scan in Diagnosis of Neuroblastoma Osseous Infiltrates; Comparative Study

Imaging: When to get MRI, CT or PET-CT?

objectives Pitfalls and Pearls in PET/CT imaging Kevin Robinson, DO Assistant Professor Department of Radiology Michigan State University

Transcription:

PET/MR:Techniques, Indications and Applications Franz Wolfgang Hirsch Professor and Head of the Department of Pediatric Radiology University Hospital Leipzig / Germany Children s Hospital University Leipzig

Structure and Function Need of Image Fusion? Hardware Fusion Software Fusion PET/CT SPECT/CT PET/MR PET/MR for the rest of us? Medical Inovation of the Year (2000) Niche Product (2004) Innovation for Children? (2010) Baum K.G. et al :Algorithm Generated Schemes for PET/MR Image Fusion J Digit Imaging (2011) 1031 1043.

PET-MR in Children? 1. Why PET/MR? 2. How does PET/MR work? 3. Why children? 4. Application 5. Own examples 6. Trouble Hirsch FW et al.: PET/MR in children. Initial clinical experience in paediatric oncology using an integrated PET/MR scanner. Pediatr Radiol. 2013 Jul;43(7):860-75.

Why PET/MR? Single modalities can only see a part of the whole Morphology Physiology Biochemistry MR anatomy, flow, perfusion, diffusion, function PET perfusion, function Quelle: Siemens PET/MR complementary methods

PET/MR Concepts Tandem vs. Integration MR PET MR / PET Tandem PET / MR Integrated PET / MR + Easier to avoid interferences - No simultaneous registration - Longer examination time + Simultaneous MR and PET + Best image coregistration + Higher throughput Source: Siemens

Attenuation Correction T1 out-of-phase T1 in-phase Fat image Water image µ-map Attenuation correction for PET DIXON-Sequence! Eiber, M. et al., Value of a Dixon-based MR/PET attenuation correction sequence for the localization and evaluation of PET-positive lesions Eur J Nucl Med Mol Imaging 38 (9), 2011

Problem with Attenuation Correction T1 out-of-phase T1 in-phase Fat image Water image µ-map Small pulmonary nodules are not well recognized in Dixon sequence Schäfer JF et al: Simultaneous whole-body PET/MR imaging in comparison to PET/CT in pediatric oncology: initial results. Radiology 2014

Problem with Attenuation Correction Small pulmonary nodules are PET negative 7 years old girl with rhabdomyosarcoma

Significantly lower radiation exposure (compared with PET-CT) Why Children? Chawla SC et al: Estimated cumulative radiation dose from PET/CT in children with malignancies: a 5-year retrospective review. Pediatr Radiol. 2010 May PET/CT : 24.8 msv Radiation exposure PET: 4.6 msv (3 msv)

Demands Application 1. No diagnostic loss compared to conventional MR studies 2. Acceptable time (45min) 3. Not only additive benefit but symbiotic value" of the two modalities Practical realization Limitation of number and duration of the sequences Field strength of 3.0 T is used for time reduction

MR Sequences optional DIXON PET (AC) PET PET PET PET PET MDS = Move during scan technicque Dixon (AC) TIRM cor TIRM cor respiratorytriggered TIRM cor respiratorytriggered TIRM cor TIRM cor TIRM cor TIRM tra TIRM tra respiratorytriggered TIRM tra respiratorytriggered TIRM tra TIRM tra TIRM tra DWI tra DWI tra DWI tra DWI tra DWI tra DWI tra FLAIR, T2 T1KM respiratory-triggered T2-TSE tra, cor T2 TSE FS tra VIBE dynamic CE T1FLASH 2D FS tra CE T1FLASH 2D FS tra CE T1 SE FS CE T1 SE FS CE PET TIRM + PET 18 FDG-PET TIRM cor TIRM tra DWI tra T1 SE FS CE

Radionuclides and Tracers

90% 18 FDG PET Radionuclides 5 % 11 and C Methionin Tracers PET Visualization of glucose transport and glucose uptake Visualization of protein synthesis / diagnostic of low grade glioma Fluorin Desoxy glucose 2% 68 Ga DOTATOC Somatostatin receptor imaging: Neuroendocrine tumors, meningioma

90% 18 FDG PET Visualization of glucose transport and glucose uptake 5 % 11 C Methionin PET Visualization of protein synthesis / diagnostic of low grade glioma 2% 68 Ga DOTATOC Somatostatin receptor imaging: Neuroendocrine tumors, meningioma

90% 18 FDG PET Visualization of glucose transport and glucose uptake 5 % 11 C Methionin PET Visualization of protein synthesis / diagnostic of low grade glioma Fluorin Desoxy Glucose 3% 18 F-DOPA PET higher sensitivity than 123I-MIBG Scintigraphy in neuroblastoma 2% 68 Ga DOTATOC Somatostatin receptor imaging: Neuroendocrine tumors, meningioma Dihydroxyphenylalanine

PET/MR Indications 1. Oncological diseases with disseminated tumor spread staging 2. Treatment response restaging 3. Therapy planning biopsy - surgery Testicular tumor with retroperitoneal metastases Supraclavicular lymph nodes and a liver metastasis 14 years MR PET/MR PET

Staging: Burkitt lymphoma cervical, 2.5 year old boy The MR finding of the left-sided lymph nodes is not pathological (lymph node size left <1.5 cm) In PET +++ Lymph nodes involvement on both sides In 10% of our patients with lymphomas it comes to an upstaging after PET-MR.

Restaging : Acute myloid leucemia, extranodal involvement Residual tumor or scar? 15 year old girl 06 th May 07 th June 08 th August No complete remission: surgery

Staging: Mixed neuroblastoma / ganglioblastoma - 1 year old boy - Originated from sympathetic trunk - Inhomogeneous FDG uptake: highly differentiated tumor tissue

Fluoro dihydroxy phenyl alanine 18 F-FDOPA PET in neurobalstoma demonstrated a higher sensitivity than 123I-MIBG scintigraphy Meng-Yao Lu* J Characterization of Neuroblastic Tumors Using 18F-FDOPA PET Nucl Med 2013; 54:42 49

18 F-FDOPA PET in neurobalstoma demonstrated a higher sensitivity than 123I-MIBG scintigraphy Meng-Yao Lu* J Characterization of Neuroblastic Tumors Using 18F-FDOPA PET Nucl Med 2013; 54:42 49

Examples Head and Brain

Patient Zimmermann, Rudi, geb. 27.10.2005 Refractory epilepsy without MR lesion 18 FDG-PET 6 year old girl Usfull only in patients with missing MR lesions 18 FDG-PET Interictal hypoperfusion / hypometabolism around of focus

65 Ga DOTATOC-PET meningioma of the optic nerve Retroorbital mass 7 year old boy 65 Ga DOTATOC-PET 65 Ga DOTATOC-PET

11 C-methionine-PET in multifocal brain tumor: Hot spot biopsy 11 C-methionine-PET 11 C-methionine-PET 11 C-methionine-PET

11 C-methionine-PET Hot spot biopsy Anaplastic astrocytoma grade III

Summary PET/MR in Children 1 instead of 2 studies High soft tissue contrast by MR +functional information by PET Simultaneous data acquisition Faster than sequential studies and more comfortable for patient More detailed information on nature and distribution of lesions Most accurate spatial allocation (hot spot biopsy / surgery) Important for Children Significantly lower radiation exposure than PET / CT

Thank you for your attention! Pet- Special thanks to MR Dr. Ina Sorge, MD, Paediatric Radiology Dr. Regine Kluge, MD PhD Nuclear medicine Dr. D. Wolf, Siemens AG Dr. H. Christiansen, MD, PhD, Paediatric oncology www.espr2018.de Berlin / Germany